MedTrace Logo

Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT06800651 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2025-07-03

No results posted yet for this study

Summary

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants with Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Conditions

  • ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Interventions

DRUG

JMKX003142 will be administered orally

JMKX003142 will be administered orally

DRUG

Plcacebo

matched to JMKX003142

Sponsors & Collaborators

  • Jemincare

    lead INDUSTRY

Principal Investigators

  • Hong Zhang, Ph.D · Peking University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-13
Primary Completion
2027-02-28
Completion
2027-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06800651 on ClinicalTrials.gov